Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04667507 · ClinicalTrials.gov registry record · Phase 4

Pharmacokinetics of Aqueous Dexamethasone

A Phase 4 study of Pharmacokinetics and Aqueous Dexamethasone, sponsored by Frank A. Bucci, Jr., M.D..

Completed
Registry status
Phase 4
Development phase
102
Enrollment target
1
Study location

NCT04667507 is a Phase 4 study of Pharmacokinetics and Aqueous Dexamethasone that has completed, run by Frank A. Bucci, Jr., M.D.. The registered enrollment target is 102 participants, above the 59-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04667507, a Phase 4 study of Pharmacokinetics and Aqueous Dexamethasone, has completed, sponsored by Frank A. Bucci, Jr., M.D..

COMPLETED
Registry status
Phase 4
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The study is being done to measure the absorption of the DEXTENZA implant and inflammation concentration levels in the eye.

Interventions

  • DRUG Dexamethasone Ophthalmic implant

Study Locations (1)

Pennsylvania

  • Bucci Laser Vision - Wilkes-Barre

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2021-01-01
Est. Completion 2022-06-22
Phase Phase 4

Sponsor

Frank A. Bucci, Jr., M.D.

4 total trials

What the Registry Record Tells You About NCT04667507

The ClinicalTrials.gov registry entry for NCT04667507 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (73% higher). The listed sponsor is Frank A. Bucci, Jr., M.D., which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Dexamethasone Ophthalmic implant is the first listed.

NCT04667507 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04667507 about?

NCT04667507 is a clinical study titled "Pharmacokinetics of Aqueous Dexamethasone". The study is being done to measure the absorption of the DEXTENZA implant and inflammation concentration levels in the eye.

What is the current status of trial NCT04667507?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2021-01-01. Estimated completion is 2022-06-22.

What conditions does trial NCT04667507 study?

This clinical trial studies the following conditions: Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response.

What interventions are being tested in trial NCT04667507?

The interventions under investigation include: Dexamethasone Ophthalmic implant (DRUG).

Who is sponsoring clinical trial NCT04667507?

This trial is sponsored by Frank A. Bucci, Jr., M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04667507 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.